Choose Your Country or Region

Cemiplimab (anti-PD-1)

Synonyms: REGN-2810, cemiplimab-rwlc

Catalog No.A2022 Purity: 99.3%

Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.

Click to purchase the isotype control of Cemiplimab (anti-PD-1)

Selleck's Cemiplimab (anti-PD-1) has been cited by 1 Publication

Purity & Quality Control

Batch: Purity: 99.3% Protein concentration: 5 mg/ml Endotoxin Level: <1 EU/mg

99.3

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description	Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
Features	Human IgG4

In Vitro
In vitro	In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.^[1]
Cell Research:	Objective: T cell activation bioassays Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 4-6 h Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Objective: T cell activation bioassays Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 72 h Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

In Vitro

In vitro

In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.^[1]

Cell Research:

Objective: T cell activation bioassays
Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 4-6 h
Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Objective: T cell activation bioassays
Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 72 h
Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

In Vivo
In vivo	Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.^[1]
Animal Research	Objective: MC38 mouse colon carcinoma Animal Models: adult human PD-1 knock-in mice Formulation: -- Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Objective: pharmacokinetic (PK) study Animal Models: cynomolgus monkeys (Macaca fascicularis) Formulation: -- Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg Administration: i.v. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

References
[1] Elena Burova, et al. Mol Cancer Ther. 2017 May;16(5):861-870.

References

[1] Elena Burova, et al. Mol Cancer Ther. 2017 May;16(5):861-870.

Product Details

CAS No.	1801342-60-8
Isotype	Human IgG4
Source	HEK293
Formulation	PBS buffer. Contains no stabilizers or preservatives
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field